The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.

Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.

AI can spot patterns in the data from blood tests that can give an early warning of disease. AI is trained to spot warning signs in blood tests AI can spot patterns in the data from blood tests ...

Some of Novartis AG (NYSE:NVS)’s key drugs are its prostate cancer drug Pluvicto, heart disease drug Leqvio, leukemia treatment Scemblix, and breast cancer treatment Kisqali. Among these ...

Asciminib (Scemblix) has reinforced its position in the chronic myeloid leukemia (CML) treatment landscape, as updated 96-week data demonstrated its superiority over standard-of-care tyrosine kinase ...

Novartis announced positive, longer-term results from the pivotal phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 961. The study ...

Novartis's current product portfolio and pipeline are central to its growth strategy. Key products such as Cosentyx, Pluvicto, Kisqali, and Scemblix are expected to drive the company's mid-term ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated sustained ...